Intratumoral injection of IL-12 plasmid DNA – results of a phase I/IB clinical trial

Leroy P, Slos P, Homann H, Erbs P, Poitevin Y, Regulier E et al. Cancer immunotherapy by direct in vivo transfer of immunomodulatory genes. Res Immunol 1998; 49: 681–684.

Rakhmilevich AL, Janssen K, Turner J, Culp J, Yang N-S . Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12. Hum Gene Ther 1997; 8: 1303–1311.

Cavallo F, Signorelli P, Giovarelli M, Musiani P, Modesti A, Brunda MJ et al. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst 1997; 89: 1049–1058.

Fernandez NC, Levraud JP, Haddada H, Perricaudet M, Kourilsky P . High frequency of specific CD8+ T cells in the tumor and blood is associated with efficient local IL-12 gene therapy of cancer. J Immunol 1999; 162: 609–617.

Lode HN, Dreier T, Xiang R, Varki NM, Kang AS, Reisfeld R . Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. Proc Natl Acad Sci USA 1998; 95: 2475–2480.

Yao L, Sgadari C, Furuke K, Bloom ET, Teruya-Feldstein J, Tosato G . Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 1999; 93: 1612–1621.

Pham-Nguyen KB, Yang W, Saxena R, Thung SN, Woo SL, Chen SH . Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma. Int J Cancer 1999; 81: 813–819.

Kodama T, Takeda K, Shimozato O, Hayakawa Y, Atsuta M, Kobayashi K et al. Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. Eur J Immunol 1999; 29: 1390–1396.

Watanabe M, Fenton RG, Wigginton JM, McCormick KL, Volker KM, Fogler WE et al. Intradermal delivery of IL-12 naked DNA induces systemic NK cell activation and Th1 response in vivo that is independent of endogenous IL-12 production. J Immunol 1999; 163: 1943–1950.

Rakhmilevich AL, Janssen K, Hao Z, Sondel PM, Yang N-S . Interleukin 12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T cell-independent mechanism. Cancer Gene Therapy 2000; 7: 826–838.

Cui J, Shin T, Kawano T, Sato H, Kondo I, Toura I et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 1997; 278: 1623–1626.

Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ et al. Recombinant IL-12 administration induces tumor regression in associated with IFN-γ production. J Immunol 1994; 153: 1697–1706.

Brunda MJ, Luistro L, Hendrzak JA, Fountoulakis M, Garotta G, Gately MK . Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. J Immunother Emphas Tumor Immunol 1995; 17: 71–75.

Manetti R, Gerosa F, Giudizi MG, Biagiotti R, Parronchi P, Piccinni MP et al. Interleukin 12 induces stable priming for interferon γ (IFN-γ) producing during differentiation of human T helper (Th) cells and transient IFN-γ production in established Th2 cells clones. J Exp Med 1994; 179: 1273–1283.

Gately MK, Warrier RR, Honasoge S, Carvajal DM, Faherty DA, Connaughton SE et al. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. Int Immunol 1994; 6: 157–167.

Tannenbaum CS, Wicker N, Armstrong D, Tubbs R, Finke J, Bukowski RM et al. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol 1996; 156: 693–699.

Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA . The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 1998; 161: 927–932.

Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J . Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995; 87: 581–586.

Rakhmilevich AL, Turner J, Ford MJ, McCadbe D, Sun WH, Sondel PM et al. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA 1996; 93: 6291–6296.

Tahara H, Zitvogel L, Storkus WJ, Robbins PD, Lotze MT . Murine models of cancer cytokine gene therapy using interleukin-12. Ann N Y Acad Sci 1996; 795: 275–283.

Golab J, Zagozdzon R . Antitumor effects of interleukin-12 in pre-clinical and early clinical studies. Int J Mol Med 1999; 3: 537–544.

Rook AH, Wood GS, Yoo EK, Elenitsas R, Kao DM, Sherman ML et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999; 94: 902–908.

Marshall E . Cancer trial of interleukin-12 halted. Science 1995; 268: 1555.

Car BD, Eng VM, Lipman JM, Anderson TD . The toxicology of interleukin-12: A review. Tox Path 1999; 27: 58–63.

Miller DG, Adam MA, Miller AD . Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990; 10: 4239–4242.

Hurley MJ, Bradford HF, O'Hare K, Stern GM, Uchida K . Neural toxicity of retroviruses. Neurosci Lett 1996; 220: 66–68.

Bramson JL, Hitt M, Addison CL, Muller WJ, Gauldie J, Graham FL . Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther 1996; 7: 1995–2002.

Nomura T, Nakajima S, Kawabata K, Yamashita F, Takakura Y, Hashida M . Intratumoral pharmacokinetics and in vivo gene expression of naked plasmid DNA and its cationic liposome complexes after direct gene transfer. Cancer Res 1997; 57: 2681–2686.

Addison CL, Bramso JL, Hitt MM, Muller WJ, Gauldie J, Graham FL . Intratumoral coinjection of adenoviral vectors expression IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Therapy 1998; 5: 1400–1409.

Lehrman S . Virus treatment questioned after gene therapy death. Nature 1999; 40: 517–518.

Saffran DC, Horton HM, Yankauchas MA, Anderson D, Barnhart KM, Abai AM et al. Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: Induction of CD8+ T-cell immunity. Cancer Gene Ther 1998; 5: 321–330.

Colombo MP, Vagliani M, Spreafico F, Parenza M, Chiodoni C, Melani C et al. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res 1996; 56: 2531–2534.

Rakhmilevich AL, Timmins JG, Janssen K, Pohlmann EL, Sheehy MJ, Yang NS . Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: a direct comparison with systemic IL-12 protein therapy. J Immunother 1999; 22: 135–144.

Weber SM, Shi FS, Heise C, Warner T, Mahvi DM . Interleukin-12 gene transfer results in CD8-dependent regression of murine CT26 liver tumors. Ann Surgical Oncol 1998; 6: 186–194.

Oshikawa K, Shi F-S, Rakhmilevich AL, Sondel PM, Mahvi DM, Yang NS . Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1 β converting enzyme cDNA. Proc Natl Aca Sci USA 1999; 96: 13351–13356.

Tahara H, Zitvogel L, Storkus WJ, Zeh III HJ, McKinney TG, Schreiber RD et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995; 154: 6466–6474.

Zitvogel L, Tahara H, Robbins PD, Storkus WJ, Clarke MR, Nalesnik MA et al. Cancer immunotherapy of established tumors with IL-12 Effective delivery by genetically engineered fibroblasts. J Immunol 1995; 155: 1393–1403.

Missol E, Sochanik A, Szala S . Introduction of murine IL-4 gene into B16 (F10) melanoma tumors by direct gene transfer with DNA–liposome complexes. Cancer Lett 1995; 97: 189–193.

Parker SE, Ducharme S, Norman J, Wheeler CJ . Tissue distribution of the cytofectin component of a plasmid-DNA/cationic lipid complex following intravenous administration in mice. Hum Gene Ther 1997; 8: 393–401.

Stephan DJ, Yang ZY, San H, Simari RD, Wheeler CJ, Felgner PL et al. A new cationic liposome DNA complex enhances the efficiency of arterial gene transfer in vivo. Hum Gene Ther 1996; 7: 1803–1812.

Blezinger P, Freimark BD, Matar M, Wilson E, Singhal A, Min W et al. Intratracheal Administration of interleukin 12 plasmid-cationic lipid complexes inhibits murine lung metastases. Hum Gene Ther 1999; 10: 723–731.

Horton HM, Anderson D, Hernandez P, Barnhart KM, Norman JA, Parker SE . A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha. Proc Natl Acad Sci USA 1999; 96: 1553–1558.

Mendiratta SK, Quezada A, Matar M, Wang J, Hebel HL, Long S et al. Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity. Gene Therapy 1999; 6: 833–839.

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. JNCI 2000; 92: 205–216.

Mahvi DM, Burkholder JK, Turner J, Culp J, Malter JS, Sondel PM et al. Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells: implications for a clinically relevant tumor vaccine. Hum Gene Ther 1996; 7: 1535–1543.

Schultz J, Pavlovic J, Strack B, Nawrath M, Moelling K . Long-lasting anti-metastatic efficiency of interleukin 12-encoding plasmid DNA. Hum Gene Ther 1999; 10: 407–417.

Popovic D, El-Shami KM, Vadai E, Feldman M, Tzehoval E, Eisenbach L et al. Antimetastatic vaccination against Lewis lung carcinoma with autologous tumor cells modified to express murine Interleukin 12. Clin Exp Met 1998; 7: 623–632.

Puisieux I, Odin L, Poujol D, Moingeon P, Tartaglia J, Cox W et al. Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity. Hum Gene Ther 1998; 9: 2481–2492.

Yahata T, Watanabe K, Ohta A, Sato N, Santo K, Abe N et al. Accumulation of IL-12-activated antitumor effector cells into lymph nodes of tumor-bearing mice. Immunol Lett 1998; 61: 127–133.

Imboden M, Shi F, Pugh TD, Freud AG, Thom NJ, Hank JA et al. Safety of IL-12 gene therapy against cancer: A murine biodistribution and toxicity study. Hum Gene Ther 2003; 14: 1037–1048.

Nair RE, Jong YS, Jones SA, Sharma A, Mathiowitz E, Egilmez NK . IL-12 + GM-CSF microsphere therapy induces eradication of advanced spontaneous tumors in her-2/neu transgenic mice but fails to achieve long-term cure due to the inability to maintain effector T-cell activity. J Immunother 2006; 29: 10–20.